Johnson & Johnson Reports 6.6% Revenue Growth to $25.3 Billion in Q2 2026

Johnson & Johnson reported its financial results for the fiscal second quarter and six months ended June 28, 2026, revealing a total revenue of $25.3 billion for the quarter, a 6.6% increase from $23.7 billion in the same period last year. For the first half of the fiscal year, the company achieved sales of $49.4 billion, up 8.2% from $45.6 billion in the prior year. The net earnings for the second quarter were $5.5 billion, with diluted earnings per share at $2.27, compared to $5.5 billion and $2.29 per share in the same quarter of 2025. The company’s gross profit margin improved slightly to 68.2% from 67.9% year-over-year.

The company experienced notable changes in its operational performance, particularly in its Innovative Medicine segment, which saw sales increase by 9.4% to $31.8 billion for the first half of 2026. This growth was driven by strong performances in oncology products, particularly DARZALEX and CARVYKTI, which reported increases of 20.6% and 55.1%, respectively. However, the segment faced challenges from declining sales of STELARA due to biosimilar competition, which negatively impacted overall sales growth. The MedTech segment also reported a 6.0% increase in sales to $17.6 billion, with growth across various franchises, including cardiovascular and surgical products.

Strategically, Johnson & Johnson announced its intention to acquire Firefly Bio, Inc. for $1 billion, which is expected to enhance its capabilities in the Innovative Medicine segment. The acquisition is anticipated to close in the third quarter of 2026, pending regulatory approvals. Additionally, the company is progressing with its planned separation of the Orthopaedics business, which is expected to be completed within 18 to 24 months from the initial announcement in October 2025.

Operationally, Johnson & Johnson reported a total employee headcount of approximately 134,000 as of June 28, 2026. The company continues to focus on geographic expansion, with international sales contributing significantly to overall revenue growth. The U.S. market accounted for $14.5 billion of the second-quarter sales, while international sales reached $10.8 billion, reflecting a 5.7% increase. The company also noted a positive currency impact on its international sales, which contributed to the overall revenue growth.

Looking ahead, Johnson & Johnson anticipates continued challenges from biosimilar competition, particularly affecting STELARA and SIMPONI. The company expects to maintain its focus on innovation and operational efficiency to drive future growth. The effective tax rate for the fiscal six months was reported at 15.5%, down from 17.8% in the previous year, which may provide additional financial flexibility. The company remains committed to its dividend policy, having declared a cash dividend of $1.34 per share for the second quarter of 2026.